Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Evolus < Previous 1 2 Next > Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance July 31, 2024 From Evolus Via Business Wire Tickers EOLS Evolus to Hold Investor Day on September 12, 2024 July 31, 2024 From Evolus Via Business Wire Tickers EOLS Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference July 25, 2024 From Evolus Via Business Wire Tickers EOLS Evolus to Report Second Quarter Financial Results on July 31, 2024 July 17, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Announces Appointment of Albert G. White III to Board of Directors July 01, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products June 24, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain June 12, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting May 20, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit May 15, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports First Quarter 2024 Results and Provides Business Update May 07, 2024 From Evolus Via Business Wire Tickers EOLS Evolus to Report First Quarter Financial Results on May 7, 2024 April 23, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® April 17, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 12, 2024 From Evolus Via Business Wire Tickers EOLS Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference March 26, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock March 11, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 08, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance March 07, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Announces Results from European Head-to-Head Filler Trial March 01, 2024 From Evolus Via Business Wire Tickers EOLS Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences February 27, 2024 From Evolus Via Business Wire Tickers EOLS Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 February 22, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 09, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance January 16, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 12, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications January 04, 2024 From Evolus Via Business Wire Tickers EOLS Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe December 20, 2023 From Evolus Via Business Wire Tickers EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 08, 2023 From Evolus Via Business Wire Tickers EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 10, 2023 From Evolus Via Business Wire Tickers EOLS < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.